SI
IONS icon

Sofinnova Investments’s Ionis Pharmaceuticals IONS Stock Holding History

Sofinnova Investments’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8,476
Closed -$374K – 63
2018
Q1 		$374K Buy
+8,476
New +$431K 0.06% 36

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Sofinnova Investments's IONS Position: Q2 2018 in Review

Sofinnova Investments sold out of Ionis Pharmaceuticals (IONS) in Q2 2018, closing a stake of 8,476 shares — an estimated $374K sold.

Sofinnova Investments first reported a position in IONS in Q1 2018 and held it in 1 quarter. The position peaked at $374K in Q1 2018. 307 funds tracked by Wall St. Rank hold IONS as of Q2 2018.

  • Sofinnova Investments reported no remaining Ionis Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Sofinnova Investments sold 8,476 Ionis Pharmaceuticals shares in Q2 2018, an estimated $374K.
  • Sofinnova Investments first reported a position in Ionis Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Sofinnova Investments's Ionis Pharmaceuticals position peaked at $374K in Q1 2018.
  • 307 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2018.

Based on Sofinnova Investments's 13F filing for Q2 2018, filed 14 Aug 2018.